Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px
Document › Details

GNA Biosolutions GmbH. (11/13/17). "Press Release: GNA Biosolutions Reveals New Ultrafast PCR Platform at Medica". Düsseldorf.

Region Region Düsseldorf
  Country Germany
Organisation Organisation GNA Biosolutions GmbH
Products Product Pharos V8 real-time PCR system
  Product 2 MEDICA 2017 Düsseldorf (COMPAMED 2017)
Person Person Krieg-Schneider, Frank (GNA Biosolutions 201607– Managing Director before Qiagen VP Global Head of Strategic Alliances)
     


Groundbreaking nucleic acid detection technology using nanomaterials


GNA Biosolutions GmbH, a molecular technology company based in Martinsried, Germany, today announced the launch of Pharos V8, the world’s first Laser PCR® platform. Pharos V8, an ultrafast PCR instrument for in vitro research use, will be showcased at the Medica Trade Fair (Exhibition Hall 3, Booth E93) from November 13-16.

The patented technology behind the Pharos V8 platform is Laser PCR®. Laser PCR® operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR® uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.

The Pharos V8 is the company’s first platform to come on the market, with additional product launches planned over the next two years. Key features of the Pharos V8 include:

> An open platform for universal PCR assay development
> Ultrafast real-time nucleic acid detection in 10 minutes or less
> Intuitive interface with easy-to-use software that can be accessed remotely

Frank Krieg-Schneider, CEO of GNA Biosolutions states, “We are excited to present our first Laser PCR® platform, the Pharos V8, at this year’s Medica. We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”


About GNA Biosolutions:

GNA Biosolutions is a molecular technology company specializing in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences.

GNA Biosolutions develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.

   
Record changed: 2018-03-25

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px

More documents for GNA Biosolutions GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px